These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 32999455)

  • 61. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps.
    Beatty GL; O'Hara M
    Pharmacol Ther; 2016 Oct; 166():30-9. PubMed ID: 27373504
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors.
    Leuci V; Mesiano G; Gammaitoni L; Aglietta M; Sangiolo D
    Curr Gene Ther; 2014 Feb; 14(1):52-62. PubMed ID: 24365144
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CAR T Cell Therapy for Hematological Malignancies.
    Yang X; Wang GX; Zhou JF
    Curr Med Sci; 2019 Dec; 39(6):874-882. PubMed ID: 31845217
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.
    Curran KJ; Pegram HJ; Brentjens RJ
    J Gene Med; 2012 Jun; 14(6):405-15. PubMed ID: 22262649
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy.
    Pang Y; Hou X; Yang C; Liu Y; Jiang G
    Mol Cancer; 2018 May; 17(1):91. PubMed ID: 29769134
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Next-generation CAR T cells to overcome current drawbacks.
    Lundh S; Maji S; Melenhorst JJ
    Int J Hematol; 2021 Nov; 114(5):532-543. PubMed ID: 32594314
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Chimeric antigen receptor-redirected T cells return to the bench.
    Geldres C; Savoldo B; Dotti G
    Semin Immunol; 2016 Feb; 28(1):3-9. PubMed ID: 26797495
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CAR T‑cell therapy for gastric cancer: Potential and perspective (Review).
    Long B; Qin L; Zhang B; Li Q; Wang L; Jiang X; Ye H; Zhang G; Yu Z; Jiao Z
    Int J Oncol; 2020 Apr; 56(4):889-899. PubMed ID: 32319561
    [TBL] [Abstract][Full Text] [Related]  

  • 70. New targets and technologies for CAR-T cells.
    Freitag F; Maucher M; Riester Z; Hudecek M
    Curr Opin Oncol; 2020 Sep; 32(5):510-517. PubMed ID: 32657796
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
    Chen L; Qiao D; Wang J; Tian G; Wang M
    Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
    Li F; Zhang T; Cao L; Zhang Y
    Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
    [TBL] [Abstract][Full Text] [Related]  

  • 73. CAR-Ts: new perspectives in cancer therapy.
    Abrantes R; Duarte HO; Gomes C; Wälchli S; Reis CA
    FEBS Lett; 2022 Feb; 596(4):403-416. PubMed ID: 34978080
    [TBL] [Abstract][Full Text] [Related]  

  • 74. CAR-T cells, from principle to clinical applications.
    Bourbon E; Ghesquières H; Bachy E
    Bull Cancer; 2021 Oct; 108(10S):S4-S17. PubMed ID: 34920806
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.
    Jindal V; Arora E; Masab M; Gupta S
    Med Oncol; 2018 May; 35(6):84. PubMed ID: 29728788
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
    Yang Z; Wang Y
    Chin Med J (Engl); 2023 Oct; 136(19):2285-2296. PubMed ID: 37358555
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Utilization of CAR T Cell Therapy in Pediatric Patients.
    Szenes V; Curran KJ
    Semin Oncol Nurs; 2019 Oct; 35(5):150929. PubMed ID: 31526551
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Engineering strategies to safely drive CAR T-cells into the future.
    Rossi M; Breman E
    Front Immunol; 2024; 15():1411393. PubMed ID: 38962002
    [TBL] [Abstract][Full Text] [Related]  

  • 80. CAR T-cell therapies in China: rapid evolution and a bright future.
    Hu Y; Feng J; Gu T; Wang L; Wang Y; Zhou L; Hong R; Tan Su Yin E; Zhang M; Lu P; Huang H
    Lancet Haematol; 2022 Dec; 9(12):e930-e941. PubMed ID: 36455608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.